Park and colleagues demonstrated that the persistent inhibition of MAO through selegiline, which is an irreversible and selective MAO-B inhibitor of the propargylamine type, may not lead to the enhancement of cognitive deficits in animal models of AD during prolonged treatment [52]. The gene discussed is MAOB; the disease is Alzheimer disease.